Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Cash from Investing Activities data on file, last reported at -$477.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 194.83% year-over-year to -$477.9 million; the trailing twelve-month figure through Mar 2026 stood at -$2.6 billion (down 24.35% YoY), and the FY2025 full-year result was -$1.6 billion, up 39.73% from the prior year.
• Cash from Investing Activities rose to -$477.9 million in Q1 2026, from -$847.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $503.9 million in Q1 2025 to a low of -$1.4 billion in Q3 2022.
• A 5-year average of -$463.1 million and a median of -$477.9 million in 2026 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities slumped 5102.47% in 2023 and soared 681.55% in 2025, its largest moves.
• Tracing RPRX's Cash from Investing Activities over 5 years: stood at $414.7 million in 2022, then plunged by 341.16% to -$1.0 billion in 2023, then soared by 49.45% to -$505.6 million in 2024, then slumped by 67.69% to -$847.8 million in 2025, then jumped by 43.63% to -$477.9 million in 2026.
• Business Quant data shows RPRX's Cash from Investing Activities at -$477.9 million in Q1 2026, -$847.8 million in Q4 2025, and -$958.3 million in Q3 2025.